Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102108 | 0.90 | HRH3 (0.41) | HRH3SMN1; SMN2LMNAPIK3CDEPHX1 | |
| SCHEMBL14277287 | 0.89 | HSD11B1 (0.35) | HSD11B1 | |
| SCHEMBL12563470 | 0.82 | SMN1; SMN2 (0.34) | HRH3CHRM3SMN1; SMN2PIK3CDEPHX1 | |
| SCHEMBL16154793 | 0.81 | HRH3 (0.37) | HRH3CHRM3SMN1; SMN2EPHX1HSD11B1 | |
| Fluoride SCHEMBL29251637 | 0.79 | HRH3 (0.36) | HRH3CHRM3SMN1; SMN2EPHX1HSD11B1 | |
| Hydrochloric Acid SCHEMBL30212674 | 0.79 | GNAO1 (0.39) | HRH3CHRM3SMN1; SMN2GNAO1 | |
| SCHEMBL13967023 | 0.78 | GNAO1 (0.42) | HRH3SMN1; SMN2LMNAEPHX1GNAO1 | |
| SCHEMBL23560328 | 0.78 | HRH3 (0.40) | HRH3SMN1; SMN2EPHX1HSD11B1GNAO1 | |
| SCHEMBL20227964 | 0.78 | CCR2 (0.34) | HSD11B1 | |
| SCHEMBL24477279 | 0.78 | SLC6A4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | HRH3 3387/4885CHRM3 4812/4885SMN1; SMN2 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.